GH Research (NasdaqGM:GHRS) put fresh clinical data in front of investors with full Phase 2a results for inhaled GH001 in postpartum depression, along with new oral presentations accepted for the CINP 2026 congress.

The stock has eased over the past month despite the latest clinical update, with a 30 day share price return of about 1% lower. However, momentum over longer periods remains strong, including a 90 day share price return of 39.77% and a 1 year total shareholder return of 65.52% that points to rising investor interest in the story.

If this kind of clinical progress has your attention, it can be useful to look across the sector and compare other healthcare focused AI opportunities using the 40 healthcare AI stocks.

With GH Research still loss making, no current revenue, a value score of 1 and a market cap of about US$1.45b, the key question is whether recent clinical progress justifies today’s valuation or if markets already price in future growth.

Preferred Price to Book of 5.5x: Is it justified?

GH Research currently trades at a P/B of 5.5x, compared with an industry average of 2.2x and a peer average of 15.2x. This puts the stock at a premium to the broader US pharmaceuticals group but below its closer peer set.

P/B compares the market value of a company to its net assets on the balance sheet. This can be a useful reference point for clinical stage biopharmaceutical companies that have little or no revenue and are still loss making.

For GH Research, the higher P/B relative to the wider industry suggests investors are willing to pay more for each dollar of book value. This may reflect interest in its mebufotenin pipeline and recent share price performance. At the same time, the discount to peer averages indicates that the market is not assigning the highest tier valuation seen in the group.

Against the US pharmaceuticals industry average of 2.2x, the current 5.5x P/B is well above that benchmark. Anyone looking at the stock through this lens is judging whether the clinical assets and balance sheet justify more than double the sector multiple.

Result: Price-to-book of 5.5x (OVERVALUED)

However, the story could change quickly if future trial data disappoints, or if the company’s loss making position and lack of revenue weigh more heavily on sentiment.

Next Steps

If this all feels finely balanced, it is worth reviewing the facts yourself and moving quickly to form your own view, starting with these 2 important warning signs.

Looking for more investment ideas?

If you are serious about finding your next opportunity, do not stop at a single stock. Put a few targeted screeners to work and see what stands out.

• Focus on quality at a discount and see which companies currently stand out in the 44 high quality undervalued stocks.
• Strengthen your income stream by scanning the 8 dividend fortresses that combine higher yields with staying power.
• Stay ahead of the crowd by checking the screener containing 20 high quality undiscovered gems before attention and capital rush in.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.